Voyager Therapeutics, Inc. VYGR · Stock Open Voyager Therapeutics, Inc. in new tab
Voyager Therapeutics, Inc. Analysis (VYGR)
Is Voyager Therapeutics, Inc. a good investment? Voyager Therapeutics, Inc. (VYGR) is currently trading at 3.00 USD. Market analysts have a consensus price target of 14.89 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 6.45. This relatively low multiple may signal that Voyager Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Voyager Therapeutics, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -1.56.
Investor FAQ
Does Voyager Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Voyager Therapeutics, Inc.?
Voyager Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -1.98.
Company Profile
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Community Discussion